APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vascular Protective Agents

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Vascular Protective Agents Industry Growth and Trends Forecast to 2032

27 December 2025129 pages

Choose your research edition.

Industry ResearchVascular Protective Agents Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Vascular Protective Agents Industry Growth and Trends Forecast to 2032129 pages · $3,450 USDMarket StructureGlobal Vascular Protective Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vascular Protective Agents Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Vascular Protective Agents Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

The global Vascular Protective Agents market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Vascular Protective Agents is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Vascular Protective Agents is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vascular Protective Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Vascular Protective Agents include Chongqing Huasen Pharmaceutical Co., Ltd., Yantai Dongcheng Pharmaceutical Group Co., Ltd., Xi'an Janssen Pharmaceutical Co., Ltd., Wuhan Aimin Pharmaceutical Co., Ltd., Tonghua Xindongri Pharmaceutical Co., Ltd., Sichuan Xieli Pharmaceutical Co., Ltd., Sichuan Feideli Pharmaceutical Co., Ltd., Shanxi Huakang Pharmaceutical Co., Ltd. and Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Vascular Protective Agents market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Vascular Protective Agents market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Vascular Protective Agents market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Vascular Protective Agents.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Vascular Protective Agents market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Vascular Protective Agents Market by Company

Chongqing Huasen Pharmaceutical Co., Ltd.

Yantai Dongcheng Pharmaceutical Group Co., Ltd.

Xi'an Janssen Pharmaceutical Co., Ltd.

Wuhan Aimin Pharmaceutical Co., Ltd.

Tonghua Xindongri Pharmaceutical Co., Ltd.

Sichuan Xieli Pharmaceutical Co., Ltd.

Sichuan Feideli Pharmaceutical Co., Ltd.

Shanxi Huakang Pharmaceutical Co., Ltd.

Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd.

Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.

Mayinglong Pharmaceutical Group Co., Ltd.

Jilin Jinsheng Pharmaceutical Co., Ltd.

Hunan Yige Pharmaceutical Co., Ltd.

Hubei Keyi Pharmaceutical Co., Ltd.

Guangxi Hercules Pharmaceutical Co., Ltd.

Chengdu Yazhong Biopharmaceutical Co., Ltd.

Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd.

STELLA

Stanex

Sebela Pharmaceuticals Inc.

Pfizer

Manus Aktteva Biopharma LLP

Hepac

Globela Pharma

Bioiberica

Advacare Pharma

Vascular Protective Agents Segment by Type

Diosmin (Citrus Flavonoids)

Polysaccharide Polysulfate

Complex Carrageenan Esters

Heparin

Aescin

Trexerutin

Vascular Protective Agents Segment by Application

Hospital

Clinic

Other

Vascular Protective Agents Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vascular Protective Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vascular Protective Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vascular Protective Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Vascular Protective Agents manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Vascular Protective Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Diosmin (Citrus Flavonoids) Table 2. Major Company of Polysaccharide Polysulfate Table 3. Major Company of Complex Carrageenan Esters Table 4. Major Company of Heparin Table 5. Major Company of Aescin Table 6. Major Company of Trexerutin Table 7. Global Vascular Protective Agents Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Vascular Protective Agents Sales by Type (2021-2026) & (K Units) Table 9. Global Vascular Protective Agents Sales Market Share in Volume by Type (2021-2026) Table 10. Global Vascular Protective Agents Sales by Type (2021-2026) & (US$ Million) Table 11. Global Vascular Protective Agents Sales Market Share in Value by Type (2021-2026) Table 12. Global Vascular Protective Agents Price by Type (2021-2026) & (US$/Unit) Table 13. Global Vascular Protective Agents Sales by Type (2027-2032) & (K Units) Table 14. Global Vascular Protective Agents Sales Market Share in Volume by Type (2027-2032) Table 15. Global Vascular Protective Agents Sales by Type (2027-2032) & (US$ Million) Table 16. Global Vascular Protective Agents Sales Market Share in Value by Type (2027-2032) Table 17. Global Vascular Protective Agents Price by Type (2027-2032) & (US$/Unit) Table 18. North America Vascular Protective Agents Sales by Type (2021-2026) & (K Units) Table 19. North America Vascular Protective Agents Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Vascular Protective Agents Sales by Type (2021-2026) & (K Units) Table 21. Europe Vascular Protective Agents Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Vascular Protective Agents Sales by Type (2021-2026) & (K Units) Table 23. Asia-Pacific Vascular Protective Agents Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Vascular Protective Agents Sales by Type (2021-2026) & (K Units) Table 25. Latin America Vascular Protective Agents Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Vascular Protective Agents Sales by Type (2021-2026) & (K Units) Table 27. Middle East and Africa Vascular Protective Agents Sales by Type (2021-2026) & (US$ Million) Table 28. Vascular Protective Agents Industry Trends Table 29. Vascular Protective Agents Industry Drivers Table 30. Vascular Protective Agents Industry Opportunities and Challenges Table 31. Vascular Protective Agents Industry Restraints Table 32. Global Vascular Protective Agents Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Vascular Protective Agents Revenue Market Share by Company (2021-2026) Table 34. Global Vascular Protective Agents Sales by Company (2021-2026) & (K Units) Table 35. Global Vascular Protective Agents Sales Share by Company (2021-2026) Table 36. Global Vascular Protective Agents Market Price by Company (2021-2026) & (US$/Unit) Table 37. Global Vascular Protective Agents Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Vascular Protective Agents Major Company Production Sites and Headquarters Table 39. Global Vascular Protective Agents Company, Product Type & Application Table 40. Global Vascular Protective Agents Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Vascular Protective Agents by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Vascular Protective Agents Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Vascular Protective Agents Sales by Region (2021-2026) & (K Units) Table 45. Global Vascular Protective Agents Sales Market Share in Volume by Region (2021-2026) Table 46. Global Vascular Protective Agents Sales by Region (2021-2026) & (US$ Million) Table 47. Global Vascular Protective Agents Sales Market Share in Value by Region (2021-2026) Table 48. Global Vascular Protective Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 49. Global Vascular Protective Agents Sales by Region (2027-2032) & (K Units) Table 50. Global Vascular Protective Agents Sales Market Share in Volume by Region (2027-2032) Table 51. Global Vascular Protective Agents Sales by Region (2027-2032) & (US$ Million) Table 52. Global Vascular Protective Agents Sales Market Share in Value by Region (2027-2032) Table 53. Global Vascular Protective Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 54. Global Vascular Protective Agents Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Vascular Protective Agents Sales by Application (2021-2026) & (K Units) Table 56. Global Vascular Protective Agents Sales Market Share in Volume by Application (2021-2026) Table 57. Global Vascular Protective Agents Sales by Application (2021-2026) & (US$ Million) Table 58. Global Vascular Protective Agents Sales Market Share in Value by Application (2021-2026) Table 59. Global Vascular Protective Agents Price by Application (2021-2026) & (US$/Unit) Table 60. Global Vascular Protective Agents Sales by Application (2027-2032) & (K Units) Table 61. Global Vascular Protective Agents Sales Market Share in Volume by Application (2027-2032) Table 62. Global Vascular Protective Agents Sales by Application (2027-2032) & (US$ Million) Table 63. Global Vascular Protective Agents Sales Market Share in Value by Application (2027-2032) Table 64. Global Vascular Protective Agents Price by Application (2027-2032) & (US$/Unit) Table 65. North America Vascular Protective Agents Sales by Application (2021-2026) & (K Units) Table 66. North America Vascular Protective Agents Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Vascular Protective Agents Sales by Application (2021-2026) & (K Units) Table 68. Europe Vascular Protective Agents Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Vascular Protective Agents Sales by Application (2021-2026) & (K Units) Table 70. Asia-Pacific Vascular Protective Agents Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Vascular Protective Agents Sales by Application (2021-2026) & (K Units) Table 72. Latin America Vascular Protective Agents Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Vascular Protective Agents Sales by Application (2021-2026) & (K Units) Table 74. Middle East and Africa Vascular Protective Agents Sales by Application (2021-2026) & (US$ Million) Table 75. Chongqing Huasen Pharmaceutical Co., Ltd. Company Information Table 76. Chongqing Huasen Pharmaceutical Co., Ltd. Business Overview Table 77. Chongqing Huasen Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Chongqing Huasen Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 79. Chongqing Huasen Pharmaceutical Co., Ltd. Recent Development Table 80. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Company Information Table 81. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Business Overview Table 82. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Vascular Protective Agents Product Portfolio Table 84. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Recent Development Table 85. Xi'an Janssen Pharmaceutical Co., Ltd. Company Information Table 86. Xi'an Janssen Pharmaceutical Co., Ltd. Business Overview Table 87. Xi'an Janssen Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Xi'an Janssen Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 89. Xi'an Janssen Pharmaceutical Co., Ltd. Recent Development Table 90. Wuhan Aimin Pharmaceutical Co., Ltd. Company Information Table 91. Wuhan Aimin Pharmaceutical Co., Ltd. Business Overview Table 92. Wuhan Aimin Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Wuhan Aimin Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 94. Wuhan Aimin Pharmaceutical Co., Ltd. Recent Development Table 95. Tonghua Xindongri Pharmaceutical Co., Ltd. Company Information Table 96. Tonghua Xindongri Pharmaceutical Co., Ltd. Business Overview Table 97. Tonghua Xindongri Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Tonghua Xindongri Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 99. Tonghua Xindongri Pharmaceutical Co., Ltd. Recent Development Table 100. Sichuan Xieli Pharmaceutical Co., Ltd. Company Information Table 101. Sichuan Xieli Pharmaceutical Co., Ltd. Business Overview Table 102. Sichuan Xieli Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Sichuan Xieli Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 104. Sichuan Xieli Pharmaceutical Co., Ltd. Recent Development Table 105. Sichuan Feideli Pharmaceutical Co., Ltd. Company Information Table 106. Sichuan Feideli Pharmaceutical Co., Ltd. Business Overview Table 107. Sichuan Feideli Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Sichuan Feideli Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 109. Sichuan Feideli Pharmaceutical Co., Ltd. Recent Development Table 110. Shanxi Huakang Pharmaceutical Co., Ltd. Company Information Table 111. Shanxi Huakang Pharmaceutical Co., Ltd. Business Overview Table 112. Shanxi Huakang Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Shanxi Huakang Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 114. Shanxi Huakang Pharmaceutical Co., Ltd. Recent Development Table 115. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Company Information Table 116. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Business Overview Table 117. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 119. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Recent Development Table 120. Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Company Information Table 121. Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Business Overview Table 122. Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 124. Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Recent Development Table 125. Mayinglong Pharmaceutical Group Co., Ltd. Company Information Table 126. Mayinglong Pharmaceutical Group Co., Ltd. Business Overview Table 127. Mayinglong Pharmaceutical Group Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Mayinglong Pharmaceutical Group Co., Ltd. Vascular Protective Agents Product Portfolio Table 129. Mayinglong Pharmaceutical Group Co., Ltd. Recent Development Table 130. Jilin Jinsheng Pharmaceutical Co., Ltd. Company Information Table 131. Jilin Jinsheng Pharmaceutical Co., Ltd. Business Overview Table 132. Jilin Jinsheng Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Jilin Jinsheng Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 134. Jilin Jinsheng Pharmaceutical Co., Ltd. Recent Development Table 135. Hunan Yige Pharmaceutical Co., Ltd. Company Information Table 136. Hunan Yige Pharmaceutical Co., Ltd. Business Overview Table 137. Hunan Yige Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Hunan Yige Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 139. Hunan Yige Pharmaceutical Co., Ltd. Recent Development Table 140. Hubei Keyi Pharmaceutical Co., Ltd. Company Information Table 141. Hubei Keyi Pharmaceutical Co., Ltd. Business Overview Table 142. Hubei Keyi Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Hubei Keyi Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 144. Hubei Keyi Pharmaceutical Co., Ltd. Recent Development Table 145. Guangxi Hercules Pharmaceutical Co., Ltd. Company Information Table 146. Guangxi Hercules Pharmaceutical Co., Ltd. Business Overview Table 147. Guangxi Hercules Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Guangxi Hercules Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 149. Guangxi Hercules Pharmaceutical Co., Ltd. Recent Development Table 150. Chengdu Yazhong Biopharmaceutical Co., Ltd. Company Information Table 151. Chengdu Yazhong Biopharmaceutical Co., Ltd. Business Overview Table 152. Chengdu Yazhong Biopharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. Chengdu Yazhong Biopharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 154. Chengdu Yazhong Biopharmaceutical Co., Ltd. Recent Development Table 155. Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Company Information Table 156. Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Business Overview Table 157. Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 158. Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 159. Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Recent Development Table 160. STELLA Company Information Table 161. STELLA Business Overview Table 162. STELLA Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 163. STELLA Vascular Protective Agents Product Portfolio Table 164. STELLA Recent Development Table 165. Stanex Company Information Table 166. Stanex Business Overview Table 167. Stanex Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 168. Stanex Vascular Protective Agents Product Portfolio Table 169. Stanex Recent Development Table 170. Sebela Pharmaceuticals Inc. Company Information Table 171. Sebela Pharmaceuticals Inc. Business Overview Table 172. Sebela Pharmaceuticals Inc. Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 173. Sebela Pharmaceuticals Inc. Vascular Protective Agents Product Portfolio Table 174. Sebela Pharmaceuticals Inc. Recent Development Table 175. Pfizer Company Information Table 176. Pfizer Business Overview Table 177. Pfizer Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 178. Pfizer Vascular Protective Agents Product Portfolio Table 179. Pfizer Recent Development Table 180. Manus Aktteva Biopharma LLP Company Information Table 181. Manus Aktteva Biopharma LLP Business Overview Table 182. Manus Aktteva Biopharma LLP Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 183. Manus Aktteva Biopharma LLP Vascular Protective Agents Product Portfolio Table 184. Manus Aktteva Biopharma LLP Recent Development Table 185. Hepac Company Information Table 186. Hepac Business Overview Table 187. Hepac Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 188. Hepac Vascular Protective Agents Product Portfolio Table 189. Hepac Recent Development Table 190. Globela Pharma Company Information Table 191. Globela Pharma Business Overview Table 192. Globela Pharma Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 193. Globela Pharma Vascular Protective Agents Product Portfolio Table 194. Globela Pharma Recent Development Table 195. Bioiberica Company Information Table 196. Bioiberica Business Overview Table 197. Bioiberica Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 198. Bioiberica Vascular Protective Agents Product Portfolio Table 199. Bioiberica Recent Development Table 200. Advacare Pharma Company Information Table 201. Advacare Pharma Business Overview Table 202. Advacare Pharma Vascular Protective Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 203. Advacare Pharma Vascular Protective Agents Product Portfolio Table 204. Advacare Pharma Recent Development Table 205. North America Vascular Protective Agents Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 206. North America Vascular Protective Agents Sales by Country (2021-2026) & (K Units) Table 207. North America Vascular Protective Agents Sales Market Share by Country (2021-2026) Table 208. North America Vascular Protective Agents Sales Forecast by Country (2027-2032) & (K Units) Table 209. North America Vascular Protective Agents Sales Market Share Forecast by Country (2027-2032) Table 210. North America Vascular Protective Agents Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 211. North America Vascular Protective Agents Market Size by Country (2021-2026) & (US$ Million) Table 212. North America Vascular Protective Agents Market Share by Country (2021-2026) Table 213. North America Vascular Protective Agents Market Size Forecast by Country (2027-2032) & (US$ Million) Table 214. North America Vascular Protective Agents Market Share Forecast by Country (2027-2032) Table 215. Europe Vascular Protective Agents Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 216. Europe Vascular Protective Agents Sales by Country (2021-2026) & (K Units) Table 217. Europe Vascular Protective Agents Sales Market Share by Country (2021-2026) Table 218. Europe Vascular Protective Agents Sales Forecast by Country (2027-2032) & (K Units) Table 219. Europe Vascular Protective Agents Sales Market Share Forecast by Country (2027-2032) Table 220. Europe Vascular Protective Agents Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 221. Europe Vascular Protective Agents Market Size by Country (2021-2026) & (US$ Million) Table 222. Europe Vascular Protective Agents Market Share by Country (2021-2026) Table 223. Europe Vascular Protective Agents Market Size Forecast by Country (2027-2032) & (US$ Million) Table 224. Europe Vascular Protective Agents Market Share Forecast by Country (2027-2032) Table 225. Asia-Pacific Vascular Protective Agents Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 226. Asia-Pacific Vascular Protective Agents Sales by Country (2021-2026) & (K Units) Table 227. Asia-Pacific Vascular Protective Agents Sales Market Share by Country (2021-2026) Table 228. Asia-Pacific Vascular Protective Agents Sales Forecast by Country (2027-2032) & (K Units) Table 229. Asia-Pacific Vascular Protective Agents Sales Market Share Forecast by Country (2027-2032) Table 230. Asia-Pacific Vascular Protective Agents Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 231. Asia-Pacific Vascular Protective Agents Market Size by Country (2021-2026) & (US$ Million) Table 232. Asia-Pacific Vascular Protective Agents Market Share by Country (2021-2026) Table 233. Asia-Pacific Vascular Protective Agents Market Size Forecast by Country (2027-2032) & (US$ Million) Table 234. Asia-Pacific Vascular Protective Agents Market Share Forecast by Country (2027-2032) Table 235. Latin America Vascular Protective Agents Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 236. Latin America Vascular Protective Agents Sales by Country (2021-2026) & (K Units) Table 237. Latin America Vascular Protective Agents Sales Market Share by Country (2021-2026) Table 238. Latin America Vascular Protective Agents Sales Forecast by Country (2027-2032) & (K Units) Table 239. Latin America Vascular Protective Agents Sales Market Share Forecast by Country (2027-2032) Table 240. Latin America Vascular Protective Agents Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 241. Latin America Vascular Protective Agents Market Size by Country (2021-2026) & (US$ Million) Table 242. Latin America Vascular Protective Agents Market Share by Country (2021-2026) Table 243. Latin America Vascular Protective Agents Market Size Forecast by Country (2027-2032) & (US$ Million) Table 244. Latin America Vascular Protective Agents Market Share Forecast by Country (2027-2032) Table 245. Middle East and Africa Vascular Protective Agents Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 246. Middle East and Africa Vascular Protective Agents Sales by Country (2021-2026) & (K Units) Table 247. Middle East and Africa Vascular Protective Agents Sales Market Share by Country (2021-2026) Table 248. Middle East and Africa Vascular Protective Agents Sales Forecast by Country (2027-2032) & (K Units) Table 249. Middle East and Africa Vascular Protective Agents Sales Market Share Forecast by Country (2027-2032) Table 250. Middle East and Africa Vascular Protective Agents Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 251. Middle East and Africa Vascular Protective Agents Market Size by Country (2021-2026) & (US$ Million) Table 252. Middle East and Africa Vascular Protective Agents Market Share by Country (2021-2026) Table 253. Middle East and Africa Vascular Protective Agents Market Size Forecast by Country (2027-2032) & (US$ Million) Table 254. Middle East and Africa Vascular Protective Agents Market Share Forecast by Country (2027-2032) Table 255. Key Raw Materials Table 256. Raw Materials Key Suppliers Table 257. Vascular Protective Agents Distributors List Table 258. Vascular Protective Agents Customers List Table 259. Research Programs/Design for This Report Table 260. Authors List of This Report Table 261. Secondary Sources Table 262. Primary Sources List of Figures Figure 1. Vascular Protective Agents Image Figure 2. Global Vascular Protective Agents Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vascular Protective Agents Market Size (2021-2032) & (US$ Million) Figure 4. Global Vascular Protective Agents Sales (2021-2032) & (K Units) Figure 5. Diosmin (Citrus Flavonoids) Image Figure 6. Global Diosmin (Citrus Flavonoids) Sales YoY Growth (2021-2032) & (K Units) Figure 7. Polysaccharide Polysulfate Image Figure 8. Global Polysaccharide Polysulfate Sales YoY Growth (2021-2032) & (K Units) Figure 9. Complex Carrageenan Esters Image Figure 10. Global Complex Carrageenan Esters Sales YoY Growth (2021-2032) & (K Units) Figure 11. Heparin Image Figure 12. Global Heparin Sales YoY Growth (2021-2032) & (K Units) Figure 13. Aescin Image Figure 14. Global Aescin Sales YoY Growth (2021-2032) & (K Units) Figure 15. Trexerutin Image Figure 16. Global Trexerutin Sales YoY Growth (2021-2032) & (K Units) Figure 17. Global Vascular Protective Agents Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Vascular Protective Agents Market Share by Type 2025 VS 2032 Figure 19. North America Vascular Protective Agents Sales Market Share in Volume by Type in 2025 Figure 20. North America Vascular Protective Agents Sales Market Share in Value by Type in 2025 Figure 21. Europe Vascular Protective Agents Sales Market Share in Volume by Type in 2025 Figure 22. Europe Vascular Protective Agents Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Vascular Protective Agents Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Vascular Protective Agents Sales Market Share in Value by Type in 2025 Figure 25. Latin America Vascular Protective Agents Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Vascular Protective Agents Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Vascular Protective Agents Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Vascular Protective Agents Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Vascular Protective Agents Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Hospital Image Figure 32. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 33. Clinic Image Figure 34. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 35. Other Image Figure 36. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 37. Global Vascular Protective Agents Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Vascular Protective Agents Market Share by Application 2025 VS 2032 Figure 39. North America Vascular Protective Agents Sales Market Share in Volume by Application in 2025 Figure 40. North America Vascular Protective Agents Sales Market Share in Value by Application in 2025 Figure 41. Europe Vascular Protective Agents Sales Market Share in Volume by Application in 2025 Figure 42. Europe Vascular Protective Agents Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Vascular Protective Agents Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Vascular Protective Agents Sales Market Share in Value by Application in 2025 Figure 45. Latin America Vascular Protective Agents Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Vascular Protective Agents Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Vascular Protective Agents Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Vascular Protective Agents Sales Market Share in Value by Application in 2025 Figure 49. North America Vascular Protective Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. North America Vascular Protective Agents Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Vascular Protective Agents Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Vascular Protective Agents Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Vascular Protective Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Europe Vascular Protective Agents Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Vascular Protective Agents Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Vascular Protective Agents Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Vascular Protective Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Asia-Pacific Vascular Protective Agents Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Vascular Protective Agents Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Vascular Protective Agents Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Vascular Protective Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Latin America Vascular Protective Agents Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Vascular Protective Agents Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Vascular Protective Agents Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Vascular Protective Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 66. Middle East and Africa Vascular Protective Agents Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Vascular Protective Agents Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Vascular Protective Agents Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Vascular Protective Agents Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Vascular Protective Agents Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Diosmin (Citrus Flavonoids)
  • Polysaccharide Polysulfate
  • Complex Carrageenan Esters
  • Heparin
  • Aescin
  • Trexerutin
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Chongqing Huasen Pharmaceutical Co., Ltd.
  • Yantai Dongcheng Pharmaceutical Group Co., Ltd.
  • Xi'an Janssen Pharmaceutical Co., Ltd.
  • Wuhan Aimin Pharmaceutical Co., Ltd.
  • Tonghua Xindongri Pharmaceutical Co., Ltd.
  • Sichuan Xieli Pharmaceutical Co., Ltd.
  • Sichuan Feideli Pharmaceutical Co., Ltd.
  • Shanxi Huakang Pharmaceutical Co., Ltd.
  • Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd.
  • Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.
  • Mayinglong Pharmaceutical Group Co., Ltd.
  • Jilin Jinsheng Pharmaceutical Co., Ltd.
  • Hunan Yige Pharmaceutical Co., Ltd.
  • Hubei Keyi Pharmaceutical Co., Ltd.
  • Guangxi Hercules Pharmaceutical Co., Ltd.
  • Chengdu Yazhong Biopharmaceutical Co., Ltd.
  • Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd.
  • STELLA
  • Stanex
  • Sebela Pharmaceuticals Inc.
  • Pfizer
  • Manus Aktteva Biopharma LLP
  • Hepac
  • Globela Pharma
  • Bioiberica
  • Advacare Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Vascular Protective Agents Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Vascular Protective Agents Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Vascular Protective Agents Market by Type
  6. 1.3.1 Diosmin (Citrus Flavonoids)
  7. 1.3.2 Polysaccharide Polysulfate
  8. 1.3.3 Complex Carrageenan Esters
  9. 1.3.4 Heparin
  10. 1.3.5 Aescin
  11. 1.3.6 Trexerutin
  12. 1.4 Global Vascular Protective Agents Market Size by Type
  13. 1.4.1 Global Vascular Protective Agents Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Vascular Protective Agents Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Vascular Protective Agents Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Vascular Protective Agents Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Vascular Protective Agents Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Vascular Protective Agents Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Vascular Protective Agents Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Vascular Protective Agents Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Vascular Protective Agents Industry Trends
  2. 2.2 Vascular Protective Agents Industry Drivers
  3. 2.3 Vascular Protective Agents Industry Opportunities and Challenges
  4. 2.4 Vascular Protective Agents Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Vascular Protective Agents Revenue (2021-2026)
  2. 3.2 Global Top Players by Vascular Protective Agents Sales (2021-2026)
  3. 3.3 Global Top Players by Vascular Protective Agents Price (2021-2026)
  4. 3.4 Global Vascular Protective Agents Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vascular Protective Agents Major Company Production Sites & Headquarters
  6. 3.6 Global Vascular Protective Agents Company, Product Type & Application
  7. 3.7 Global Vascular Protective Agents Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Vascular Protective Agents Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Vascular Protective Agents Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Vascular Protective Agents Tier 1, Tier 2, and Tier 3
4 Vascular Protective Agents Regional Status and Outlook
  1. 4.1 Global Vascular Protective Agents Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Vascular Protective Agents Historic Market Size by Region
  3. 4.2.1 Global Vascular Protective Agents Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Vascular Protective Agents Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Vascular Protective Agents Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Vascular Protective Agents Forecasted Market Size by Region
  7. 4.3.1 Global Vascular Protective Agents Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Vascular Protective Agents Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Vascular Protective Agents Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Vascular Protective Agents by Application
  1. 5.1 Vascular Protective Agents Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Vascular Protective Agents Market Size by Application
  6. 5.2.1 Global Vascular Protective Agents Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Vascular Protective Agents Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Vascular Protective Agents Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Vascular Protective Agents Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Vascular Protective Agents Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Vascular Protective Agents Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Vascular Protective Agents Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Vascular Protective Agents Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Chongqing Huasen Pharmaceutical Co., Ltd.
  2. 6.1.1 Chongqing Huasen Pharmaceutical Co., Ltd. Company Information
  3. 6.1.2 Chongqing Huasen Pharmaceutical Co., Ltd. Business Overview
  4. 6.1.3 Chongqing Huasen Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Chongqing Huasen Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  6. 6.1.5 Chongqing Huasen Pharmaceutical Co., Ltd. Recent Developments
  7. 6.2 Yantai Dongcheng Pharmaceutical Group Co., Ltd.
  8. 6.2.1 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Company Information
  9. 6.2.2 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Business Overview
  10. 6.2.3 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Vascular Protective Agents Product Portfolio
  12. 6.2.5 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Recent Developments
  13. 6.3 Xi'an Janssen Pharmaceutical Co., Ltd.
  14. 6.3.1 Xi'an Janssen Pharmaceutical Co., Ltd. Company Information
  15. 6.3.2 Xi'an Janssen Pharmaceutical Co., Ltd. Business Overview
  16. 6.3.3 Xi'an Janssen Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Xi'an Janssen Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  18. 6.3.5 Xi'an Janssen Pharmaceutical Co., Ltd. Recent Developments
  19. 6.4 Wuhan Aimin Pharmaceutical Co., Ltd.
  20. 6.4.1 Wuhan Aimin Pharmaceutical Co., Ltd. Company Information
  21. 6.4.2 Wuhan Aimin Pharmaceutical Co., Ltd. Business Overview
  22. 6.4.3 Wuhan Aimin Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Wuhan Aimin Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  24. 6.4.5 Wuhan Aimin Pharmaceutical Co., Ltd. Recent Developments
  25. 6.5 Tonghua Xindongri Pharmaceutical Co., Ltd.
  26. 6.5.1 Tonghua Xindongri Pharmaceutical Co., Ltd. Company Information
  27. 6.5.2 Tonghua Xindongri Pharmaceutical Co., Ltd. Business Overview
  28. 6.5.3 Tonghua Xindongri Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Tonghua Xindongri Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  30. 6.5.5 Tonghua Xindongri Pharmaceutical Co., Ltd. Recent Developments
  31. 6.6 Sichuan Xieli Pharmaceutical Co., Ltd.
  32. 6.6.1 Sichuan Xieli Pharmaceutical Co., Ltd. Company Information
  33. 6.6.2 Sichuan Xieli Pharmaceutical Co., Ltd. Business Overview
  34. 6.6.3 Sichuan Xieli Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Sichuan Xieli Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  36. 6.6.5 Sichuan Xieli Pharmaceutical Co., Ltd. Recent Developments
  37. 6.7 Sichuan Feideli Pharmaceutical Co., Ltd.
  38. 6.7.1 Sichuan Feideli Pharmaceutical Co., Ltd. Company Information
  39. 6.7.2 Sichuan Feideli Pharmaceutical Co., Ltd. Business Overview
  40. 6.7.3 Sichuan Feideli Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Sichuan Feideli Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  42. 6.7.5 Sichuan Feideli Pharmaceutical Co., Ltd. Recent Developments
  43. 6.8 Shanxi Huakang Pharmaceutical Co., Ltd.
  44. 6.8.1 Shanxi Huakang Pharmaceutical Co., Ltd. Company Information
  45. 6.8.2 Shanxi Huakang Pharmaceutical Co., Ltd. Business Overview
  46. 6.8.3 Shanxi Huakang Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Shanxi Huakang Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  48. 6.8.5 Shanxi Huakang Pharmaceutical Co., Ltd. Recent Developments
  49. 6.9 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd.
  50. 6.9.1 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Company Information
  51. 6.9.2 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Business Overview
  52. 6.9.3 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  54. 6.9.5 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Recent Developments
  55. 6.10 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.
  56. 6.10.1 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Company Information
  57. 6.10.2 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Business Overview
  58. 6.10.3 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  60. 6.10.5 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Recent Developments
  61. 6.11 Mayinglong Pharmaceutical Group Co., Ltd.
  62. 6.11.1 Mayinglong Pharmaceutical Group Co., Ltd. Company Information
  63. 6.11.2 Mayinglong Pharmaceutical Group Co., Ltd. Business Overview
  64. 6.11.3 Mayinglong Pharmaceutical Group Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Mayinglong Pharmaceutical Group Co., Ltd. Vascular Protective Agents Product Portfolio
  66. 6.11.5 Mayinglong Pharmaceutical Group Co., Ltd. Recent Developments
  67. 6.12 Jilin Jinsheng Pharmaceutical Co., Ltd.
  68. 6.12.1 Jilin Jinsheng Pharmaceutical Co., Ltd. Company Information
  69. 6.12.2 Jilin Jinsheng Pharmaceutical Co., Ltd. Business Overview
  70. 6.12.3 Jilin Jinsheng Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Jilin Jinsheng Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  72. 6.12.5 Jilin Jinsheng Pharmaceutical Co., Ltd. Recent Developments
  73. 6.13 Hunan Yige Pharmaceutical Co., Ltd.
  74. 6.13.1 Hunan Yige Pharmaceutical Co., Ltd. Company Information
  75. 6.13.2 Hunan Yige Pharmaceutical Co., Ltd. Business Overview
  76. 6.13.3 Hunan Yige Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Hunan Yige Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  78. 6.13.5 Hunan Yige Pharmaceutical Co., Ltd. Recent Developments
  79. 6.14 Hubei Keyi Pharmaceutical Co., Ltd.
  80. 6.14.1 Hubei Keyi Pharmaceutical Co., Ltd. Company Information
  81. 6.14.2 Hubei Keyi Pharmaceutical Co., Ltd. Business Overview
  82. 6.14.3 Hubei Keyi Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Hubei Keyi Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  84. 6.14.5 Hubei Keyi Pharmaceutical Co., Ltd. Recent Developments
  85. 6.15 Guangxi Hercules Pharmaceutical Co., Ltd.
  86. 6.15.1 Guangxi Hercules Pharmaceutical Co., Ltd. Company Information
  87. 6.15.2 Guangxi Hercules Pharmaceutical Co., Ltd. Business Overview
  88. 6.15.3 Guangxi Hercules Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Guangxi Hercules Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  90. 6.15.5 Guangxi Hercules Pharmaceutical Co., Ltd. Recent Developments
  91. 6.16 Chengdu Yazhong Biopharmaceutical Co., Ltd.
  92. 6.16.1 Chengdu Yazhong Biopharmaceutical Co., Ltd. Company Information
  93. 6.16.2 Chengdu Yazhong Biopharmaceutical Co., Ltd. Business Overview
  94. 6.16.3 Chengdu Yazhong Biopharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Chengdu Yazhong Biopharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  96. 6.16.5 Chengdu Yazhong Biopharmaceutical Co., Ltd. Recent Developments
  97. 6.17 Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd.
  98. 6.17.1 Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Company Information
  99. 6.17.2 Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Business Overview
  100. 6.17.3 Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  102. 6.17.5 Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Recent Developments
  103. 6.18 STELLA
  104. 6.18.1 STELLA Company Information
  105. 6.18.2 STELLA Business Overview
  106. 6.18.3 STELLA Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 STELLA Vascular Protective Agents Product Portfolio
  108. 6.18.5 STELLA Recent Developments
  109. 6.19 Stanex
  110. 6.19.1 Stanex Company Information
  111. 6.19.2 Stanex Business Overview
  112. 6.19.3 Stanex Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Stanex Vascular Protective Agents Product Portfolio
  114. 6.19.5 Stanex Recent Developments
  115. 6.20 Sebela Pharmaceuticals Inc.
  116. 6.20.1 Sebela Pharmaceuticals Inc. Company Information
  117. 6.20.2 Sebela Pharmaceuticals Inc. Business Overview
  118. 6.20.3 Sebela Pharmaceuticals Inc. Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Sebela Pharmaceuticals Inc. Vascular Protective Agents Product Portfolio
  120. 6.20.5 Sebela Pharmaceuticals Inc. Recent Developments
  121. 6.21 Pfizer
  122. 6.21.1 Pfizer Company Information
  123. 6.21.2 Pfizer Business Overview
  124. 6.21.3 Pfizer Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 Pfizer Vascular Protective Agents Product Portfolio
  126. 6.21.5 Pfizer Recent Developments
  127. 6.22 Manus Aktteva Biopharma LLP
  128. 6.22.1 Manus Aktteva Biopharma LLP Company Information
  129. 6.22.2 Manus Aktteva Biopharma LLP Business Overview
  130. 6.22.3 Manus Aktteva Biopharma LLP Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 Manus Aktteva Biopharma LLP Vascular Protective Agents Product Portfolio
  132. 6.22.5 Manus Aktteva Biopharma LLP Recent Developments
  133. 6.23 Hepac
  134. 6.23.1 Hepac Company Information
  135. 6.23.2 Hepac Business Overview
  136. 6.23.3 Hepac Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  137. 6.23.4 Hepac Vascular Protective Agents Product Portfolio
  138. 6.23.5 Hepac Recent Developments
  139. 6.24 Globela Pharma
  140. 6.24.1 Globela Pharma Company Information
  141. 6.24.2 Globela Pharma Business Overview
  142. 6.24.3 Globela Pharma Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  143. 6.24.4 Globela Pharma Vascular Protective Agents Product Portfolio
  144. 6.24.5 Globela Pharma Recent Developments
  145. 6.25 Bioiberica
  146. 6.25.1 Bioiberica Company Information
  147. 6.25.2 Bioiberica Business Overview
  148. 6.25.3 Bioiberica Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  149. 6.25.4 Bioiberica Vascular Protective Agents Product Portfolio
  150. 6.25.5 Bioiberica Recent Developments
  151. 6.26 Advacare Pharma
  152. 6.26.1 Advacare Pharma Company Information
  153. 6.26.2 Advacare Pharma Business Overview
  154. 6.26.3 Advacare Pharma Vascular Protective Agents Sales, Revenue and Gross Margin (2021-2026)
  155. 6.26.4 Advacare Pharma Vascular Protective Agents Product Portfolio
  156. 6.26.5 Advacare Pharma Recent Developments
7 North America by Country
  1. 7.1 North America Vascular Protective Agents Sales by Country
  2. 7.1.1 North America Vascular Protective Agents Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Vascular Protective Agents Sales by Country (2021-2026)
  4. 7.1.3 North America Vascular Protective Agents Sales Forecast by Country (2027-2032)
  5. 7.2 North America Vascular Protective Agents Market Size by Country
  6. 7.2.1 North America Vascular Protective Agents Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Vascular Protective Agents Market Size by Country (2021-2026)
  8. 7.2.3 North America Vascular Protective Agents Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Vascular Protective Agents Sales by Country
  2. 8.1.1 Europe Vascular Protective Agents Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Vascular Protective Agents Sales by Country (2021-2026)
  4. 8.1.3 Europe Vascular Protective Agents Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Vascular Protective Agents Market Size by Country
  6. 8.2.1 Europe Vascular Protective Agents Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Vascular Protective Agents Market Size by Country (2021-2026)
  8. 8.2.3 Europe Vascular Protective Agents Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Vascular Protective Agents Sales by Country
  2. 9.1.1 Asia-Pacific Vascular Protective Agents Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Vascular Protective Agents Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Vascular Protective Agents Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Vascular Protective Agents Market Size by Country
  6. 9.2.1 Asia-Pacific Vascular Protective Agents Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Vascular Protective Agents Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Vascular Protective Agents Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Vascular Protective Agents Sales by Country
  2. 10.1.1 South America Vascular Protective Agents Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Vascular Protective Agents Sales by Country (2021-2026)
  4. 10.1.3 South America Vascular Protective Agents Sales Forecast by Country (2027-2032)
  5. 10.2 South America Vascular Protective Agents Market Size by Country
  6. 10.2.1 South America Vascular Protective Agents Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Vascular Protective Agents Market Size by Country (2021-2026)
  8. 10.2.3 South America Vascular Protective Agents Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Vascular Protective Agents Sales by Country
  2. 11.1.1 Middle East and Africa Vascular Protective Agents Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Vascular Protective Agents Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Vascular Protective Agents Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Vascular Protective Agents Market Size by Country
  6. 11.2.1 Middle East and Africa Vascular Protective Agents Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Vascular Protective Agents Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Vascular Protective Agents Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Vascular Protective Agents Value Chain Analysis
  2. 12.1.1 Vascular Protective Agents Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Vascular Protective Agents Production Mode & Process
  7. 12.2 Vascular Protective Agents Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Vascular Protective Agents Distributors
  10. 12.2.3 Vascular Protective Agents Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst